CVR 34879524Private limited company (ApS)Fremstilling af farmaceutiske præparater (212000)Secondary industries: Engroshandel med medicinalvarer og sygeplejeartikler (464610)København KFounded 5 Dec 2012
CVR registers no owner holding 5% or more.
CVR holds no employment figures for this company.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Y-MABS THERAPEUTICS, ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexResult
-14.7K
DKK, annual report 2014
Equity
72.3K
DKK, annual report 2014
CVR registers no owner holding 5% or more.
Thomas Gaduntil 16 Aug 2016
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2014, DKK: Operating profit -14.7K, Result for the year -14.7K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2014, DKK: Total assets 81.5K, Equity 72.3K
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2013 | 2014 |
|---|---|---|
| Operating profit | -88 | -15 |
| Result for the year | -88 | -15 |
| Equity | -8 | 72 |
| Total assets | 0 | 81 |
| Credit metrics (Dandex calculations) | ||
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | |
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | |
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | |
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | |
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | |
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | |
Not every period is a full year: 2013 covers 13 months (5 Dec 2012 to 31 Dec 2013). Changes against it compare periods of different length.
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for Y-MABS THERAPEUTICS, ApS:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseCashPaid in 95,000, cash price 95.00, implied value 7,695,000 | 95.00 | 95,000 | 7,695,000 | 81,000 | |
| FoundingCashPaid in 80,000 | None | 80,000 | None | 80,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Merger (fusion), as the ceasing company (ophørende selskab)
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
12 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion. Kapitalejerne har i enighed besluttet, at der ikke skal udarbejdes en fusionsplan. Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i de deltagende selskaber må antages at være tilstrækkeligt sikrede efter fusionen.
Virksomheden er d. null opløst ved fusion med CVR-nummer: 40338683 G. Estates ApS.
Vedrørende registrering den 08.02.2019 meddeles det, at registreringen beror på en fejl. Selskabets status er under tvangsopløsning.
Binavne:
SELECT PHARMA ApS UNDER KONKURS
Konkursdekret er ophævet 29.08.2018
Likvidatorer:
Tiltrådte:
Ole Larsen, 2150 Nordhavn, den 29.08.2018.
Virksomheden tegnes af en likvidator.
Binavne:
SELECT PHARMA ApS UNDER TVANGSOPLØSNING
Konkursdekret afsagt 28.11.2016 af Sø- og Handelsrettens Skifteretsafdeling
Likvidatorer:
Fratrådte:
Ole Larsen, den 28.11.2016.
Revision:
Binavne:
SELECT PHARMA ApS UNDER KONKURS
Konkursdekret er ophævet 29.08.2018
Likvidatorer:
Tiltrådte:
Ole Larsen, 2150 Nordhavn, den 29.08.2018.
Virksomheden tegnes af en likvidator.
Binavne:
SELECT PHARMA ApS UNDER TVANGSOPLØSNING
Konkursdekret afsagt 28.11.2016 af Sø- og Handelsrettens Skifteretsafdeling
Likvidatorer:
Fratrådte:
Ole Larsen, den 28.11.2016.
Revision:
Binavne:
SELECT PHARMA ApS UNDER TVANGSOPLØSNING
Likvidatorer:
Tiltrådte:
Sø- og Handelsrettens Skifteretsafdeling har udnævnt følgende likvidatorer: Ole Larsen, 1165 København K, den 14.11.2016.
Virksomheden tegnes af en likvidator.
Virksomhedens kreditorer opfordres til at anmelde deres krav til likvidator. Krav skal anmeldes senest tre måneder fra dags dato.
Anmodning om opløsning, jf. selskabslovens § 225 sendt til Sø- og Handelsrettens Skifteretsafdeling den 16.08.2016
Direktion:
Fratrådte:
Thomas Gad, den 16.08.2016.
Revision:
Fratrådte:
GRANT THORNTON,STATSAUTORISERET REVISIONSPARTNERSELSKAB, den 16.08.2016.
Vedtægter ændret:
26.12.2014.
Kapitalforhøjelse:
kr. 1.000,00 indbetalt kontant, kurs 9.500,00.
Kapitalen udgør herefter kr. 81.000,00.
Ny adresse:
Ny Østergade 3, 1101 København K.
Vedtægter ændret:
16.09.2014.
Nyt binavn: SELECT PHARMA ApS.
Vedtægter ændret:
12.08.2013.
Nyt navn:
Y-MABS THERAPEUTICS, ApS.
Ny adresse:
c/o Thomas Gad, Malmøgade 6, 2. tv., 2100 København Ø.
Ny kommune:
København.
Stiftelsesdato:
05.12.2012.
Seneste vedtægtsdato:
05.12.2012.
Kapital:
kr. 80.000,00.
Indbetalingsmåde:
Indbetalt kontant kr. 80.000,00 til kurs 100,00.
Stifter:
Thomas Gad, den 05.12.2012.
Direktion:
Thomas Gad, den 05.12.2012.
Selskabet tegnes af direktøren.
Revision:
CVR-NR. 34209936 GRANT THORNTON,STATSAUTORISERET REVISIONSPARTNERSELSKAB, Stockholmsgade 45, 2100 København Ø, den 05.12.2012.
Første regnskabsår:
05.12.2012 - 31.12.2013.
Regnskabsår:
01.01 - 31.12.
P-number 1018113216Ny Østergade 3, 1101 København K